Targeting Ferroptosis: Pathological Mechanism and Treatment of Ischemia-Reperfusion Injury

Figure 3

Pathological mechanism and targeted therapies of ferroptosis in ischemia-reperfusion (I/R) injury-related diseases. NCOA4: nuclear receptor coactivator 4; C3G: cyanidin-3-glucoside; USP7: ubiquitin-specific protease 7; USP7 ↑: the upregulation of USP7; ELAVL1: embryonic lethal-abnormal vision like protein 1; GPX4: glutathione peroxidase 4; AA: arachidonic acid; ACSL4: acyl-CoA synthetase long-chain family 4; LPCAT3: lysophosphatidylcholine acyltransferase 3; ALOXs: arachidonate lipoxygenases; PE: phosphatidylethanolamine; OxPCs: oxidized phosphatidylcholines; USP22: ubiquitin-specific peptidase 22; DFO: deferoxamine; TFR1: transferrin receptor 1; GSH: glutathione; MIF: macrophage migration inhibitory factor; Sp1: special protein 1; SLC7A11: solute carrier family 7 member 11; NRF2: nuclear factor erythroid 2-related factor; HO-1: heme oxygenase-1; iASPP: inhibitor of apoptosis-stimulating protein of P53.